Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics has received full FDA approval for FILSPARI, a treatment for IgA nephropathy (IgAN), based on the PROTECT Study. Ligand Pharmaceuticals is entitled to a 9% royalty on worldwide net sales of FILSPARI.
September 06, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals will receive a 9% royalty on worldwide net sales of FILSPARI following its FDA approval for IgAN.
Ligand Pharmaceuticals benefits financially from the FDA approval of FILSPARI through a 9% royalty on sales, which could enhance revenue streams and positively influence the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Travere Therapeutics received full FDA approval for FILSPARI, a treatment for IgAN, which could become foundational care due to its superior long-term results.
The FDA approval of FILSPARI for IgAN is a significant milestone for Travere Therapeutics, as it positions the drug as a potential foundational treatment. This approval is likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100